
Albert David Analyst Review 2027: Sales Up 16% and Margins Recover, Profit Back in Black
Updated: 19 Nov 2026 • 2:18 pm
Posted by:

Albert David Stock Snapshot (18 Nov 2026 close)
- Current Market Price (CMP): ₹759.90
- 52-Week High / Low: ₹931.85 / ₹579.90
- Market Capitalisation: ₹430 crore
- P/E Ratio vs Industry P/E: 15.1 vs 51.5
- Latest Quarter (Q2 FY27) Revenue: ₹100.83 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹2.88 crore
Quick Answer: The Albert David analyst review 2027 finds no brokerage coverage as of November 2026. Q2 FY27 sales rose about 15.6% to ₹100.83 crore and net profit was ₹2.88 crore, against a loss of ₹3.30 crore a year ago. Operating margin improved to 11.6% from 2.9%, though a high tax rate of about 43% held back profit. H1 FY27 profit was about ₹35 crore, helped by a much stronger June quarter. At ₹759.90, the stock trades at about 15 times earnings and close to book value, so the Albert David share price target 2027 question depends on steady margins.
The Albert David analyst review 2027 covers a Kolkata-based drug maker that is part of the Kothari group and makes medicines including injectables, infusions and other formulations. Readers searching for an Albert David share price target 2027 will not find a named brokerage figure, so results and valuation guide this review.
Albert David closed at ₹759.90 on 18 November 2026, about 18% below its 52-week high of ₹931.85 and about 31% above its low of ₹579.90. This Albert David analyst review 2027 covers the September quarter and the Albert David stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Albert David Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified coverage | Not available | Not available | As of November 2026 |
No brokerage covers Albert David, and institutions hold only about 2.2%. With a market value of about ₹430 crore, it sits outside most research lists.
The stock trades at about 15 times trailing earnings, far below the industry level of about 51.5, and at about 1.03 times book value of ₹738.86 per share. This Albert David analyst review 2027 explains why the market values it near book despite recent profit growth.
Q2 FY27 Results in the Albert David Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Sales | ₹100.83 crore | ₹87.24 crore | Up 15.6% |
| Operating profit | About ₹12 crore | About ₹2.5 crore | Up sharply |
| Operating margin | 11.6% | 2.9% | Up 8.7 points |
| Net profit | ₹2.88 crore | Loss of ₹3.30 crore | Back to profit |
| EPS | ₹5.05 | Negative | Back to positive |
Sales rose 15.6% and the operating margin jumped to 11.6% from 2.9%. Net profit turned positive at ₹2.88 crore, though a tax rate of about 43%, well above the usual level near 20%, reduced the figure.
Sales have now grown year on year for four quarters in a row. For this Albert David analyst review 2027, the margin recovery is the most important change.
How Albert David Makes Money
Albert David makes and sells medicines, mainly in India.
- Injectables and infusions: hospital products such as IV fluids and injections.
- Formulations: tablets, capsules and other branded medicines.
- Hospital supply: sales to hospitals and institutions.
- Doctor-led sales: branded medicines promoted to doctors through a field force.
Sales were about ₹101.34 crore in the June quarter, up about 44%, and ₹100.83 crore in September, so H1 FY27 sales reached about ₹202 crore against about ₹158 crore a year earlier. H1 FY27 profit was about ₹35 crore against about ₹4.6 crore. Those numbers anchor this Albert David analyst review 2027.
Most of the half-year profit came from the June quarter, which was much stronger than September. Investors should treat the H1 figure with care, because one quarter carried most of the gain and the September quarter alone earned less than ₹3 crore.
The December 2025 quarter offers another reference point, with sales of about ₹89.93 crore, an operating margin of about 12% and profit of ₹15.30 crore. That suggests margins near 12% are achievable, but quarterly profit can still swing on tax and other items.
The balance sheet is improving. Borrowings fell about 18% to about ₹34 crore from September 2025, and debt to equity is low at about 0.08. With little debt, most of any margin gain can flow through to profit.
Return on equity of about 6.8% is the main reason the stock trades close to book value. If margins stay near 12% for several quarters, returns would rise and the gap to industry valuations could narrow.
Hospital products such as infusions tend to be steady, because hospitals reorder them regularly regardless of the economic cycle. That gives the business a stable base, while margins depend on raw material costs, plant use and how much of the portfolio comes from higher-margin branded products.
Growth Triggers in the Albert David Analyst Review 2027
- Margin recovery: operating margin up to 11.6%.
- Sales growth: four straight quarters of year-on-year growth.
- Lower debt: borrowings down about 18% to ₹34 crore.
- Tax normalising: a lower tax rate would lift reported profit.
- Valuation gap: a P/E far below the industry feeds the Albert David share price target 2027 debate.
Key Risks in the Albert David Analyst Review 2027
- Lumpy profits: H1 profit came mostly from one quarter.
- High tax: a 43% rate held back Q2 profit.
- Low returns: return on equity of about 6.8%.
- Price controls: government pricing rules can limit margins on some medicines.
- Low liquidity: small institutional holding, a caution in the Albert David analyst review 2027.
Compare Albert David With Other Pharma Stocks on the Univest Screener
Albert David Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (18 Nov 2026 close) | ₹759.90 |
| 52-Week High / Low | ₹931.85 / ₹579.90 |
| Market Capitalisation | ₹430 crore |
| P/E (TTM) | 15.1 |
| Industry P/E | 51.5 |
| Price to Book | 1.03 |
| Return on Equity | 6.8% |
| Debt to Equity | 0.08 |
| EPS (TTM) | ₹50.35 |
| H1 FY27 Sales / Net Profit | About ₹202 crore / ₹35 crore |
The P/E of about 15 is less than a third of the industry level, and price to book value is about 1.03. In this Albert David analyst review 2027, low returns and uneven profit explain the gap.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 62.24% | 62.24% | No change |
| Foreign Investors (FII) | 0.60% | 0.60% | No change |
| Domestic Institutions (DII) | 1.66% | 1.64% | Flat |
| Public | 35.50% | 35.53% | Flat |
The promoter group holds 62.24%, led by Kothari Investment and Industries at 41.4% and Anand Vardhan Kothari at 9.9%. Stable holdings are a neutral point in the Albert David analyst review 2027.
What to Watch After the Albert David Analyst Review 2027
- Margins: operating margin holding near 12%.
- Tax rate: a return towards normal levels.
- Sales growth: a fifth straight quarter of growth.
- Debt: further cuts in borrowings.
- Coverage: any research note would give an Albert David share price target 2027 reference.
Final Word on the Albert David Analyst Review 2027
The Albert David analyst review 2027 shows a mid-sized drug maker with rising sales, recovering margins and falling debt, though quarterly profit remains uneven. The stock trades near book value and well below industry multiples.
The Albert David stock outlook 2027 depends on steady margins and more consistent profit. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Albert David analyst review 2027 show?
It shows a return to profit with better margins. Q2 FY27 sales rose about 15.6% to ₹100.83 crore and net profit was ₹2.88 crore. A year earlier, it posted a loss of ₹3.30 crore.
Is there an Albert David share price target 2027 from brokerages?
No brokerage covers Albert David as of November 2026. The stock closed at ₹759.90 on 18 November 2026. Book value per share is about ₹738.86.
What does Albert David make?
Albert David makes medicines including injectables, infusions, tablets and other formulations. It is a Kolkata-based Kothari group company. H1 FY27 sales were about ₹202 crore.
Why was Albert David's Q2 profit low despite higher margins?
The tax rate was about 43%, well above the usual level near 20%. Operating margin still rose to 11.6% from 2.9%. Net profit was ₹2.88 crore.
Is Albert David stock undervalued based on the Albert David analyst review 2027?
The P/E of about 15 is far below the industry P/E of about 51.5. Price to book is about 1.03. Low return on equity and uneven profits explain the gap.
What risks does the Albert David analyst review 2027 highlight?
The main risks are lumpy profits, a high tax rate and low returns. Most H1 FY27 profit came from the June quarter. Government price rules can also limit margins.
What should investors track after the Albert David analyst review 2027?
Track whether operating margin holds near 12% and the tax rate normalises. Watch for a fifth straight quarter of sales growth. Further debt reduction also matters.
Recent Articles

Futures Basis Contango and Backwardation Explained: What the Gap to Spot Shows, Why Futures Trade at a Premium and How to Read It
19 November 2026

Physical Settlement vs Cash Settlement Explained: How Stock and Index Derivatives Settle, What Happens at Expiry, Margin Impact and How to Avoid Delivery
19 November 2026

Broken Wing Butterfly Explained: How the Uneven Wings Work, Payoff, Break-Even, Where Maximum Profit and Loss Sit and When Traders Use It
19 November 2026

Jade Lizard Strategy Explained: How the Three Leg Setup Works, Payoff, Break-Even, Why Upside Risk Is Removed and When Traders Use It
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Futures Basis Contango and Backwardation Explained: What the Gap to Spot Shows, Why Futures Trade at a Premium and How to Read It
Physical Settlement vs Cash Settlement Explained: How Stock and Index Derivatives Settle, What Happens at Expiry, Margin Impact and How to Avoid Delivery
Broken Wing Butterfly Explained: How the Uneven Wings Work, Payoff, Break-Even, Where Maximum Profit and Loss Sit and When Traders Use It
Jade Lizard Strategy Explained: How the Three Leg Setup Works, Payoff, Break-Even, Why Upside Risk Is Removed and When Traders Use It
Ultimate Oscillator Explained: Formula, Three Time Frames, Overbought and Oversold Levels, Divergence Signal Rules and Where It Misleads
Popular this week
Island Reversal Pattern Explained: How the Gaps Form, Bullish and Bearish Versions, Volume Clues, Entry Rules and Where It Fails

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





